Gaithersburg-based biotechnology firm GlycoMimetics “has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for the proposed initial public offering of shares of its common stock,” according to a press release.
GlycoMimetics is focused on the “discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role.”
Before you go...
Please consider supporting Technical.ly to keep our independent journalism strong. Unlike most business-focused media outlets, we don’t have a paywall. Instead, we count on your personal and organizational support.
Join our growing Slack community
Join 5,000 tech professionals and entrepreneurs in our community Slack today!
